ASTELLAS PHARMA INC.

Explore how Astellas’ tacrolimus pricing deal and API donation reshape Medicaid costs, supply chains, and future drug innovation.

Royalty deal fuels Astellas’ metabolic growth, converting future rusfertide royalties into capital to accelerate obesity & metabolic drug development.

Financial analysis of Astellas Pharma’s Q2 2026 results: stable revenue, controlled costs, and a strategic share‑buyback boosting shareholder value.

Unveiling Zydus Lifesciences’ latest unaudited Q3 2026 results: revenue growth, a finished share‑buyback, and strong compliance with Ind AS and SEBI – insights for investors.

Director of Astellas Pharma buys 10,000 shares at par, signaling confidence and reinforcing the company’s transparency and governance standards in a regulated pharma market.

FDA approves KEYTRUDA‑Padcev combo for muscle‑invasive bladder cancer, boosting survival and Merck’s oncology portfolio.

How Astellas’ Enzalutamide expansion reshapes oncology pricing, reimbursement models, and market share—unlocking $150 million in revenue and setting a new benchmark for value‑based drug delivery.

Explore how Lupin Limited’s tentative FDA approval for generic enzalutamide could reshape the U.S. oncology market, boost revenue, and spark new M&A opportunities.

Explore how Lupin’s tentative FDA approval of generic Xtandi® could reshape the prostate‑cancer market, boost patient access, and impact Astellas’ revenue.

Explore how Astellas Pharma’s legal case reshapes compliance and fuels its promising NMIBC oncology pipeline, driving future growth and investor confidence.